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ABC transporter proteins may protect haematopoietic progenitor cells from chemotherapy-induced toxicity. By using an in vitro
colony-forming assay, we found that bone marrow of Mdr1ab, Mrp1, Mdr1ab/Mrp1 knockout (KO) mice was two-, five- to 10- and
25-fold, respectively, more sensitive to vincristine than wild-type mice bone marrow. To study the impact of ABC transporters on in
vivo bone marrow sensitivity without the added complication of altered pharmacokinetics, we created chimeras of wild-type mice
transplanted with bone marrow from wild-type, Mrp1, Mdr1ab or Mdr1ab/Mrp1 KO donor mice. Following a single bolus injection of
vincristine, the chimeras transplanted with wild-type or Mdr1ab KO marrow cells showed no reductions in WBC. A significant
reduction was observed in Mrp1 KO chimeras, but the most pronounced effect was observed in mice receiving bone marrow from
Mdr1ab/Mrp1 KO mice. A pharmacokinetic analysis in wild-type and KO mice showed that the absence of P-gp reduced the body
clearance of vincristine, but that no further reduction occurred when Mrp1 was also absent. However, the tissue accumulation of
vincristine in tissues of these Mdr1ab/Mrp1 KO mice was further increased. This study demonstrates that the presence of multiple
drug transporters protects the bone marrow, and probably other tissues as well, against chemotherapeutic insults.
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ABC transporters such as P-glycoprotein (P-gp) provide efficient
protection against xenobiotics. As demonstrated by using knock-
out (KO) mouse models, P-gp and Breast cancer resistance protein
(Bcrp1) limit the uptake from the gastrointestinal tract of
substances, such as drugs (Sparreboom et al, 1997; Jonker et al,
2000) or potentially toxic dietary substances (Jonker et al, 2002).
Similarly, P-gp in the blood–brain barrier limits the entry of
substances into the brain (Schinkel et al, 1994, 1996). Multidrug
resistance-associated protein (Mrp1) KO mice were hypersensitive
to etoposide (Lorico et al, 1997; Wijnholds et al, 1997). Mrp1
protects the oropharyngeal mucosal layer and the testicular tubules
(Wijnholds et al, 1998) and plays a role in the blood–cerebrospinal
fluid barrier (Rao et al, 1999; Wijnholds et al, 2000).
Myelotoxicity is a common complication when treating cancer
patients with chemotherapeutic drugs. Already in 1991, Chaudhary
and Roninson (1991) showed that P-gp was present in haemato-
poietic progenitor cells, suggesting that this transporter might also
be involved in the protection of bone marrow stem cells. The role
of drug transporters in bone marrow-derived cells under in vitro
conditions was further addressed in several studies in vitro.
Mdr1ab P-gp contributed to the extrusion of the fluorophore
rhodamine 123 from haematopoietic progenitor cells (Schinkel
et al, 1997). Moreover, it was recently shown that Bcrp1 is the
transport protein responsible for the extrusion of the marker dye
Hoechst 33342 (Zhou et al, 2001; Kim et al, 2002; Scharenberg et al,
2002). Flow cytometry cell sorting of the fraction of Hoechst 33342
dull cells resulted in a highly enriched fraction of primitive
haematopoietic progenitor cells. Subsequent RT–PCR analyses of
RNA from these so-called side-population (SP) cells revealed the
presence of Mrp1, Mrp3 and Mrp4 but not Mrp2 (Zhou et al, 2001).
The role of these drug transporters in vivo is currently under
investigation. Bcrp1 appears to protect the bone marrow from
mitoxantrone-induced toxicity (Zhou et al, 2002). Johnson et al
(2001) showed that mice with compound disruptions of the Mdr1a,
Mdr1b and the Mrp1 genes (Mdr1ab/Mrp1 triple KO mice) were
about 128-fold more sensitive for i.p. vincristine. Their results
suggested that the bone marrow might be involved in the toxicity
profile, but it remained unclear whether the toxicity was directly
due to the absence of these drug transporters in the haematopoie-
tic progenitor cells or whether it was also, or even merely, a
consequence of a reduced drug clearance in these Mdr1ab/Mrp1
triple KO mice. The pharmacokinetics of vincristine has not been
documented, but it is well established that the absence of P-gp
reduces the clearance of substrate drugs, such as vinblastine (van
Asperen et al, 1996).
In the present study, we have investigated the role of P-gp and
Mrp1 in the protection of the bone marrow in vitro and in vivo.W e
have used a bone marrow transplantation model to avoid
complications in data interpretation due to differences in drug
clearance. Wild-type mice receiving whole-body irradiation at a
dose that was lethal to the bone marrow were transplanted with
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sbone marrow from donor mice deficient in Mdr1ab and/or Mrp1
genes. Animals transplanted with wild-type bone marrow were
used as control group. After their full recovery, the mice were
exposed to the anticancer drug vincristine and the bone marrow
toxicity was determined by serial analyses of haematology
parameters. In parallel experiments, the pharmacokinetics and
toxicology of vincristine in the wild-type and Mdr1ab/Mrp1 triple
KO mice were established using a selective high-performance
liquid chromatographic (HPLC) assay.
MATERIALS AND METHODS
Animals
Male wild-type, Mrp1 knockout (Wijnholds et al, 1997), Mdr1ab
double knockout (Mdr1ab DKO; animals with compound deletion
of Mdr1a and Mdr1b genes) (Schinkel et al, 1997) and Mdr1ab/
Mrp1 triple knockout (Mdr1ab/Mrp1 TKO) were used. The latter
were obtained by crossbreeding of Mrp1 KO and Mdr1ab DKO
mice. All mouse strains were backcrossed for at least seven
generations to obtain a more than 99% homogeneous FVB
background. The animals were given food (Hope Farms BV,
Woerden, The Netherlands) and acidified water ad libitum. They
were handled according to the institutional guidelines, which are
based on Dutch law and conform the standards required by the
UKCCCR guidelines (Workman et al, 1998). The animal experi-
ment committee of the Institute approved the experiments
described in this paper.
Determination of the maximum tolerated dose (MTD)
Vincristine (Pharmachemie, Haarlem, The Netherlands;
1mgml
 1) was diluted in saline and administered i.v. to wild-
type and Mdr1ab/Mrp1 TKO mice, aged 10–14 weeks, at dose
levels ranging between 0.125 and 4mgkg
 1. Animals were
monitored daily and killed when they lost more than 20% of their
initial body weight. The MTD was defined as one dose step below
the dose where more than one animal in that group had to be
killed. Necropsies were performed in wild-type and Mdr1ab/Mrp1
TKO mice receiving vincristine at or near the MTD and killed 2
days later.
Pharmacokinetics
The pharmacokinetic behaviour of vincristine in wild-type,
Mdr1ab KO and Mdr1ab/Mrp1 TKO mice, 10–14 weeks of age,
was established at a dose of 1mgkg
 1. Animals were killed at 5, 15,
30min, 1, 2 and 4h after drug administration for collection of
plasma. At 1 and 4h, a range of tissues was also collected.
Vincristine levels in plasma and tissues were analysed by HPLC
developed by us previously (Boven et al, 1999). Plasma AUC0–4h
(area under the curve) values were calculated by the linear
trapezoidal rule using standard equations (van Asperen et al, 1996)
and the clearance was calculated as Dose/AUC0–4h. Statistical tests
were performed with SPSS v11.0 (SPSS Inc., Chicago, IL, USA).
In vitro bone marrow toxicity
The toxicity of vincristine in haematopoietic progenitor cells was
tested by an in vitro colony forming unit (CFU) assay. Mouse bone
marrow progenitor cells were obtained from the femurs of FVB
mice flushed with Dulbecco’s phosphate-buffered saline solution.
After centrifugation (10min, 200g, ambient temperature), the cell
pellet was resuspended in Iscoves medium (MDM) (StemCell
Technologies Inc., Vancouver, BC, Canada) with 2% (vv
 1) fetal
calf serum (FCS). Nucleated bone marrow cells were seeded in
Methocult GF M3534 at a density of 2.5 10
5cellsml
 1 and
vincristine was added at concentrations ranging from 2.5 to
100ngml
 1. Aliquots of 1ml were plated in duplicate in uncoated
six-wells culture plates (Greiner, Alphen a/d Rijn, The Nether-
lands) and incubated for 5–6 days at 37
oCi n5 %C O 2 in
humidified air. CFUs were scored by phase-contrast light
microscopy. We have used the concentration that reduces the
number of colonies by more than 90% relative to untreated
controls (IC90) instead of IC50 because the decreasing size of the
colonies at higher drug concentrations makes accurate scoring of
their numbers difficult. Hardly any colonies were present at the
IC90 making this parameter easier to determine.
In vivo bone marrow toxicity
Wild-type mice of about 5–6 weeks of age received whole-body
irradiation of 6.8Gy (HF320 Radiobiology Constant Potential X-
ray Unit, Pantak, East Haven, CT, USA). The next morning each
mouse was i.v. injected with 1.5 to 3 10
6 nucleated bone marrow
cells from donor mice of wild-type, mrp1 KO, Mdr1ab DKO or
Mdr1ab/Mrp1 TKO genotype. After a recovery period of 6 weeks,
the mice received an i.v. bolus injection of 2mgkg
 1 of vincristine
via the tail vein. To minimise the effects of mild dehydration
occurring at this dose level of vincristine, mice were supported by
daily i.p. administrations of 1ml of saline: dextrose 5% (1:1; v/v)
for 3 days. At days 0 (before vincristine), 2, 4, 7 and 12, peripheral
blood was sampled from the tail and haematologic parameters
(WBC and Haemoglobin (Hb)) were determined on a Cell Dyn
1200 analyzer (Abbott Laboratories, Santa Clara, CA, USA).
Experiments were performed on six different occasions. At some
of these occasions, the mice receiving bone marrow of TKO mice
were also challenged with vincristine at lower dose levels (e.g. 0.5
or 1mgkg
 1). Bone marrow was obtained at the end of the
experiments from a number of randomly selected mice and used to
determine the in vitro sensitivity of the grafted bone marrow using
the in vitro bone marrow toxicity test.
PCR analyses
As a random test, the genotype of the engrafted bone marrow was
verified by PCR analyses in about 50% of all animals. DNA was
prepared from whole-blood samples of recipient animals using the
DNeasy kit (Qiagen GmbH, Hilden, Germany), according to the
manufacturer’s protocol. Disruption of genes in the KO mice
strains was achieved by replacement of relevant genomic
fragments by a selection gene, for example, hygromycin in case
of Mdr1a (4). As a result, PCR verification of the Mdr1a KO
genotype was verified by the presence and absence of bands for
hygromycin and Mdr1a, respectively.
RESULTS
We first examined the relative sensitivities of bone marrow derived
from wild type, Mrp1 KO, Mdr1ab DKO and Mdr1ab/Mrp1 TKO
mice using an in vitro CFU assay. Cell kill occurred in a dose-
dependent manner. The bone marrow of wild-type animals was
most resistant to vincristine (Table 1). Mdr1ab DKO bone marrow
cells were about two-fold more sensitive, whereas Mrp1 KO cells
were about five to 10-fold more sensitive. The absence of both drug
transporters in cells from the Mdr1ab/Mrp1 TKO mice resulted in
an about 25-fold higher susceptibility towards vincristine. These
experiments were repeated several times and although the absolute
IC90 values varied with different batches of culture medium, the
relative differences in IC90 between the bone marrow of the various
genotypes were consistent throughout these experiments.
We next investigated the MTD of vincristine in our mouse strains
(Table 2). Based on our previous experience, we selected a few dose
levels in wild-type animals (1, 2 and 4mgkg
 1). The MTD in wild-
type mice was 2mgkg
 1, where the mice experienced mild but clear
Protection of haematopoietic progenitor cells
O van Tellingen et al
1777
British Journal of Cancer (2003) 89(9), 1776–1782 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
ssigns of toxicity, including pilo-erection, and a median weight loss of
about 12% of the initial value achieved around day 2, followed by
weight gain thereafter. Only one wild-type mouse receiving 2mgkg
 1
experienced body weight loss in excess of 20%; however, this nadir
was reached at 7 days after drug administration at a time that
surviving animals were already regaining weight. It was not clear
whether this event was due to vincristine toxicity or to other causes.
Ad o s el e v e lo f4m gk g
 1 was clearly above the MTD, since five out of
five animals experienced more than 20% body weight loss.
The MTD in Mdr1ab/Mrp1 TKO mice was clearly lower at
0.5mgkg
 1, but similar macroscopic signs of toxicity were
observed. At a dose of 1mgkg
 1, two out of four animals had to
be killed (at days 4 and 5) because their body weight dropped by
more than 20%, whereas the two others survived. These results
indicate that there is a moderate increase in vincristine toxicity in
animals lacking both these drug-transporting proteins.
Toxic effects of vincristine in wild-type and Mdr1ab/Mrp1 TKO
mice were assessed by full necropsy of the animals 2 days after they
received vincristine at their respective MTD. In Mdr1ab/Mrp1 TKO
mice receiving 0.5mgkg
 1 toxicities manifested by arrested
mitoses were found in the intestines, skin, bone marrow, the
adrenal medulla and in the bases of the incisors. No evidence for
central nervous toxicity or liver toxicity was observed. In wild-type
mice receiving a dose of 2mgkg
 1, the incisors were affected and a
moderate depletion of the bone marrow was seen, but no signs of
toxicity were found in any of the other tissues, except for some
mild vacuolisation of spinal ganglion neurons.
We further investigated the pharmacokinetics of vincristine
given at a dose of 1mgkg
 1 to wild-type, Mdr1ab DKO and
Mdr1ab/Mrp1 TKO mice by sampling of blood and tissues for up
to 4h after drug administration. Although this dose level was
above the MTD in Mdr1ab/Mrp1 TKO mice, it was selected because
toxic effects are relatively mild during the first 4h and because of
the detection limit of the assay (5ngml
 1 for a 200ml plasma
sample). In line with the toxicity results there was only a moderate
reduction in the plasma clearance of vincristine (Figure 1), and this
appears to be due mainly to the absence of P-gp, since the plasma
concentration–time curves of Mdr1ab DKO and Mdr1ab/Mrp1
TKO mice are overlapping. The plasma clearance in wild-type mice
was 16.271.0mgml
 1h and was significantly (Po0.01) reduced to
12.070.6 and 12.170.5mgml
 1hi nMdr1ab DKO and Mdr1ab/
Mrp1 TKO mice, respectively. Similar as in plasma, the vincristine
levels observed in tissues of Mdr1ab DKO were significantly higher
than in wild-type mice (Figure 2). Interestingly, however, the levels
of vincristine in several tissues of Mdr1ab/Mrp1 TKO were again
significantly higher than those in Mdr1ab DKO, despite equivalent
plasma levels, suggesting that Mrp1 offers additional protection
against vincristine accumulation in these tissues. The vincristine
levels in the brain were below the limit of detection in all animals.
To avoid the complicating effects of these transporters on the
pharmacokinetics of vincristine, we investigated the consequences
of the absence of the various transporters on the bone marrow
Table 1 Toxicity of bone marrow progenitor cells (in vitro)
Conc.
(ngml
 1)
Wild
type
Mrp1
KO
Mdr1ab
DKO
Mdr1ab/Mrp1
TKO
100       
50 +     
25 +   +  
10 + 7 +  
5N D + N D  
2N D + N D 7
1N D + N D +
Bone marrow cells harvested from wild-type, Mrp1 KO, Mdr1ab DKO and Mdr1ab/
Mrp1 (TKO) mice were incubated continuously with various concentrations of
vincristine. Colonies were scored by day 5. Wells were scored with   when the
number of colonies was reduced by more than 90% relative to control wells without
the drug (IC90). 7 indicates a borderline value, whereas clearly less than 90%
reduction is marked by a + sign. ND means not determined.
Table 2 Toxicity of vincristine in mice
Decrease in body weight
Dose (mgkg
 1) Number of animals Toxic deaths Median (%) Range Day of nadir
Mdr1ab/Mrp1 TKO 0.125 9 0 1.9 0–7.9 2
0.25 13 0 3.0 0–7.4 3
0.5 9 0 10.3 4.1–19.1 4
1 4 2 20.5 14.1–27.2 3–4
Wild ype 1 5 0 4.6 3.6–7.6 2
2 5 1 12.1 10.9–20.6 2
4 5 5 23.1 21.0–25.1 4
Animals received vincristine by i.v. injection. Body weight was determined daily. Animals experiencing more than 20% body weight loss were killed and counted as toxic deaths.
The size of, especially, the highest dose groups was kept as low as possible in order to minimise the number of animals experiencing major discomfort.
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Figure 1 Plasma concentration–time profiles of vincristine. Mice
received 1mgkg
 1 of vincristine by i.v. injection. Each time point represents
at least four animals. The AUC values were calculated by the linear
trapezoidal rule and were 61.873.8, 83.174.2 and 82.473.4ngml
 1h for
wild type, Mdr1ab DKO and Mdr1ab/Mrp1 TKO, respectively. The latter
two were significantly higher (Po0.01) than the values of wild-type mice,
but not significantly different from each other.
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sin vivo using animals with transplanted bone marrows of different
genotype. By using this approach we ensured that the only
difference in these mice was in the genotype of their bone marrow.
Wild-type mice, which tolerate the highest dose of vincristine,
received whole-body irradiation at a dose of 6.8Gy. All mice that
were not supplemented with donor bone marrow died within 10
days after irradiation when the WBC and the Hb concentration had
dropped to extremely low values. With a few exceptions, the mice
that did receive bone marrow of donor mice remained in good
condition. These results show that irradiation induced bone
marrow ablation had occurred and was the primary cause of
death. Wild-type animals received donor bone marrow of either
wild-type, Mrp1 KO, Mdr1ab DKO or Mdr1ab/Mrp1 TKO mice,
and were allowed to recover for an additional 6 weeks before
receiving one cycle of vincristine chemotherapy by i.v. adminis-
tration. Most animals were treated with the MTD of vincristine for
wild-type mice (2mgkg
 1).
Both in wild type and in Mdr1ab DKO chimeras, there was no
reduction in WBC (Figure 3). On the contrary, the levels increased
after day 2, which may be due to chemotherapy-induced
recruitment of cells from the bone marrow or due to the procedure
of blood sampling from the tail vein; a procedure that may cause a
mild inflammatory response. The WBC counts in animals receiving
Mrp1 KO bone marrow had dropped significantly at day 4, but
showed a steep rebound by day 7. The most pronounced effect on
WBC was observed in mice receiving Mdr1ab/Mrp1 TKO donor
marrow. The nadir in these mice occurred at day 4 followed by a
gradual recovery to baseline values within about 12 days. The nadir
in WBC in Mdr1ab/Mrp1 chimeras was clearly dose dependent
(Figure 3: right panel).
The Hb concentrations in wild-type and Mdr1ab KO chimeras
increased slightly by day 2, which may be due to the mild
dehydration as a consequence of the toxicity occurring at this dose
of vincristine (Figure 4). In Mdr1ab/Mrp1 TKO chimeras receiving
a lower dose (0.5 or 1mgkg
 1) of vincristine, this effect was not
observed (not shown). By day 12, the Hb level in Mdr1ab/Mrp1
TKO chimeras was significantly lower than observed in the other
cohorts (Po0.001). Overall, however, the effect on Hb was less
severe than the effect on the WBC counts, which is probably due to
the longer half-life of mature red blood cells compared to
peripheral WBC.
We performed a random check whether the repopulation of the
bone marrow by donor mice was complete or only partial by
harvesting of bone marrow of animals at the end of the study,
which was and in the in vitro CFU assay. In all cases, bone marrow
derived from Mdr1ab/Mrp1 chimeras showed the same high
sensitivity to vincristine as bone marrow obtained from Mdr1ab/
Mrp1 TKO mice used as control. In addition, PCR analyses of
whole-blood samples from the mice at the end of the experiment
were used to verify the genotype of the donor bone marrow.
Although the results for the hygromycin gene (selection marker for
the Mdr1a KO allele) were consistent in all cases, we observed a
weak signal for Mdr1a in mice that received bone marrow of
Mdr1ab DKO or Mdr1ab/Mrp1 TKO donor mice. This is probably
due to the high sensitivity of the PCR assay, which detects small
quantities of host genomic DNA in the blood. It was estimated that
up to 5% of circulating nucleated cells were of wild-type origin.
DISCUSSION
This study using an in vivo model shows that the ABC-transporters
P-gp and Mrp1 protect haematopoietic progenitor cells in the bone
marrow from vincristine toxicity. The most significant effects in
WBC and Hb values were observed in mice grafted with bone
marrow from Mdr1ab/Mrp1 TKO mice. Mrp1 chimeras showed
intermediate signs of haematotoxicity, whereas no toxicity was
observed in animals that received bone marrow from Mdr1ab DKO
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Figure 2 Tissue accumulation of vincristine. Mice receiving 1mgkg
 1
were killed at 1 and 4h after drug administration. Drug levels
were determined by HPLC. Each bar represents at least four animals
and the error bar depicts the s.e. Statistical analyses were performed by
ANOVA using Bonferroni post hoc test for multiple comparisons. * Po0.05
relative to wild-type; ** Po0.05 relative to Mdr1ab DKO, otherwise not
significant.
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sor wild-type donor mice. Thus, in the case of vincristine, the two
transporters appear to function in concert in bone marrow
progenitor cells and the alternate transporter can partly or
completely compensate the loss of function of the other. Overall,
the lethality in Mdr1ab/Mrp1 TKO chimeras after challenging with
vincristine was a few percent and not higher than in animals
bearing Mdr1ab DKO, Mrp1 KO or wild-type bone marrow. This
shows that the increased haematotoxicity after single high-dose
vincristine treatment was not a dose-limiting event per se.
A pharmacokinetic analysis of vincristine showed that, relative
to wild-type mice, the plasma clearance of vincristine was reduced
in Mdr1ab DKO mice but not further reduced in Mdr1ab/Mrp1
TKO mice. This result is in line with the location of P-gp in apical
membranes of excretory organs (liver, intestines, kidneys)
(Thiebaut et al, 1987), where it is involved in detoxification by
extrusion of substrates from the body, whereas Mrp1 is mainly
located in basolateral membranes and has relatively little direct
effect on drug excretion from the body (Borst et al, 1999; Hipfner
et al, 1999). However, this study shows that the accumulation of
vincristine in tissues from Mdr1ab/Mrp1 TKO mice was clearly
enhanced relative to Mdr1ab DKO mice showing that Mrp1 offers
protection to tissues. A previous study in Mrp1 KO mice did not
find any effects on tissue distribution of etoposide (Wijnholds et al,
1997). This discrepancy may be (partly) due to the presence of P-
gp in these mice, which may be such a dominant factor that it
conceals the effects of a loss of Mrp1. However, it is also possible
that the analytical methodology (determination of total radio-
activity after administration of radiolabelled drug) was not suited
to find these differences, because it cannot discern unchanged
substrate drug from (radiolabelled) metabolites and/or degrada-
tion products. We have used a selective HPLC to determine
unchanged vincristine levels. The higher drug levels in tissues
correlates with previous reports of local organ toxicities when
Mrp1 KO mice were challenged with chemotherapeutics (Wijn-
holds et al, 1998). It thus seems likely that P-gp located at the
apical side and Mrp1 at the basolateral side of epithelia cooperate
in limiting the accumulation of compounds that are substrates of
both transporters, such as vincristine, whereas they are less
efficient for compounds that are substrate of only one of them.
Moreover, their concerted activity has also been shown in cells
expressing these transporters in a nonpolarised fashion. By using
immortalised fibroblast cell lines, it was found that both Mdr1ab
and Mrp1 are implicated in innate resistance to cytotoxic
substrates (Allen et al, 2000; Lin et al, 2002), but the strongest
effects were found in cells lacking both transporters. Our findings
of a markedly enhanced toxicity by vincristine in the in vitro bone
marrow toxicity assays are in line with these results.
The dose-limiting toxicity of vincristine in Mdr1ab/Mrp1 TKO
mice appears to be related to the effects on the gastrointestinal
tract. We found that the Mdr1ab/Mrp1 TKO mice were only about
four-fold more sensitive to vincristine than wild-type mice, which
is much less than the 128-fold reported previously (Johnson et al,
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Figure 3 In vivo bone marrow toxicity induced by vincristine: effects on
WBC. Lethally irradiated wild-type mice, which had received donor
marrow from wild-type (n¼38), Mrp1 KO (n¼33), Mdr1ab DKO
(N¼18) and Mdr1ab/Mrp1 TKO (n¼38) mice, were challenged with
2mgkg
 1 of vincristine administered by i.v. injection (upper panel). The
course of the WBC in blood is depicted as percentage of the initial value at
day 0 (arbitrarily set at 100%). * Po0.05 relative to wild type, otherwise
not significant. The lower panel depicts the results in Mdr1ab/Mrp1 TKO
donor marrow grafted mice receiving 0.5mg (n¼15), 1mg (n¼20) or
2mg (n¼21) of vincristine per kilogram and show the dose-dependent
response on WBC.
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Figure 4 In vivo bone marrow toxicity induced by vincristine: effects on
Hb levels. Lethally irradiated wild-type mice received donor marrow from
wild-type, Mrp1 KO, Mdr1ab DKO and Mdr1ab/Mrp1 (TKO) mice were
challenged by i.v. administration of 2mg of vincristine per kilogram (left
panel). The course of the haemoglobin concentration is depicted as
percentage of the initial value at day 0 (arbitrarily set at 100%). * Po0.05
relative to wild type; otherwise not significant.
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s2001). It is unlikely that the different routes of administration in
the two studies (i.p. vs i.v.) would explain this discrepancy. In our
experience, the clearance of hydrophobic drugs from the
peritoneal cavity of mice occurs rapidly. Moreover, both wild-type
and Mdr1ab/Mrp1 TKO mice received vincristine by the same
route, and the results for wild-type mice were consistent between
the two studies. The difference may be explained by differences in
drug elimination between animals in the two studies. In addition to
elimination by excretion, metabolism is also a very important
route for many drugs including vincristine. It has previously been
shown that Mdr1a KO mice maintained in our institute have a
higher expression of cytochrome P450 isoenzymes than mice of
similar genotype kept in the United States (Schuetz et al, 2000).
Consequently, clearance of vincristine might occur more rapidly in
our populations of Mdr1ab DKO and Mdr1ab/Mrp1 TKO mice,
rendering them less susceptible to vincristine.
To eliminate the effects of reductions in body clearance
of vincristine on bone marrow toxicity, we have used a bone
marrow transplantation model yielding chimeras that were
of identical wild-type genotype, except for their bone marrow
progenitor cells. The course of the WBC counts in the Mdr1ab/
Mrp1 TKO chimeras closely resembled the pattern that is usually
observed in patients experiencing chemotherapy-induced myelo-
toxicity. The nadir and return to baseline levels occurred
somewhat more abruptly, but this is most likely due to the
fact that most physiological processes in mice proceed at a higher
velocity than in humans. Interestingly, the nadir was about similar
in Mrp1 KO chimeras, but there was a very strong rebound in WBC
counts by day 7. This difference between Mrp1 KO and Mdr1ab/
Mrp1 TKO chimeras may be due to the fact that the relative
expression of ABC transporters appears to vary along the lineage
from uncommitted stem cells to mature blood cells. In mice,
CD34
  sorted SP cells appear to represent a more primitive
subpopulation of progenitor cells than CD34
þ cells (Osawa et al,
1996) and these cells contain relatively high levels of Bcrp1 and
Mdr1 mRNA, whereas Mrp1 appears to be higher in the murine
CD34
þ subpopulation of cells (Zhou et al, 2001). The absence of
Mrp1 will make this population of CD34
þ progenitor cells more
vulnerable to vincristine. A single bolus of a high dose of
vincristine given to Mrp1 KO chimeras may significantly reduce
the numbers of these precursor cells, thus eliminating part of the
maturing blood cells from the pipeline. The decline in WBC will
trigger signalling to induce a compensatory wave of haematopoi-
esis and because the population of primitive CD34
  precursor cells
is probably not so much affected due to protection by P-gp, this
can still occur effectively. In Mdr1ab/Mrp1 TKO chimeras,
however, this more primitive population of CD34
  cells is no
longer protected by P-gp and may therefore be more vulnerable to
vincristine, thus causing further delay in WBC recovery.
In this study, we have shown that a single dose of vincristine
resulted in a clear but nonlethal bone marrow toxicity, which was
Mrp1 and P-gp dependent. Repeated dosing or continuous
infusion of this G2–M cell cycle specific drug might have resulted
in greater bone marrow toxicity. More pronounced cytotoxic
effects on these primitive precursor cells have been shown in a
recent study, where irradiated mice that were transplanted with
mixtures of wild-type and Bcrp1 KO donor bone marrow were
challenged with mitoxantrone (Zhou et al, 2002). After five daily
repeated injections of 2mg of mitoxantrone per kilogram, the
relative contribution of Bcrp1 null cells in the peripheral blood
myeloid and lymphoid compartment declined to very low values
and remained low during the many weeks afterwards. In this case
with repeated dosing of mitoxantrone, it appears that the majority
of primitive Bcrp1 null stem cells have been eradicated and have
been replaced by wild-type cells. Given that mitoxantrone is also a
substrate of P-gp, we expect that the effect of this drug may be even
greater in bone marrow cells with a compound deletion of the
Mdr1ab and Bcrp1 alleles.
In conclusion, although the physiological function of P-gp, Mrp1
and other ABC-transporters in haematopoietic progenitor stem
cells is still conjectural, it is clear that they protect the cells against
chemotherapy-induced injury. Inhibition of their function, for
example, as part of drug regimens aimed to sensitise drug-resistant
tumour cells, may thus result in enhanced myelotoxicity. However,
the fact that multiple transporters with (partly) overlapping
substrate specificities are present appears to be a safety mechanism
that may render this a relatively infrequent complication.
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